cardiovascular diseases

News

Novo Nordisk's IL-6 drug flunks two more heart trials

Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.

News

Novartis hit as Lp(a) drug fails cardio outcomes trial

Novartis shares have slipped after it revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial.

News

ESC26: Can Arrowhead pierce Ionis' triglyceride armour?

Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.

News

ESC26: AZ's relaxin agonist shows promise in heart failure

An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients with heart failure.

News

ESC26: Cytokinetics' big data reveal for Myqorzo impresses

Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026.

News

Tenax trounced by phase 3 heart failure readout

Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.

Novo Nordisk's IL-6 drug flunks two more heart trials

Novartis hit as Lp(a) drug fails cardio outcomes trial

ESC26: Can Arrowhead pierce Ionis' triglyceride armour?

ESC26: AZ's relaxin agonist shows promise in heart failure

ESC26: Cytokinetics' big data reveal for Myqorzo impresses

Tenax trounced by phase 3 heart failure readout

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

cardiovascular diseases

Editor's Picks